SIGA Technologies, Inc.

NASDAQ•SIGA

CEO: Dr. Dennis E. Hruby Ph.D.

セクター: Healthcare

業種: Drug Manufacturers - Specialty & Generic

上場日: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

連絡先情報

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

時価総額

$446.85M

PER (TTM)

6.0

37.5

配当利回り

9.6%

52週高値

$9.62

52週安値

$4.95

52週レンジ

28%

順位30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

堅調 • 5.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$2.62M-73.83%

直近4四半期の推移

EPS

-$0.09-578.72%

直近4四半期の推移

フリーCF

-$10.10M+36.43%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Surge Total revenues reached $90.78M USD for nine months, up $33.53M USD from $57.25M USD reported in prior year.

Net Income Improvement Nine-month net income $28.71M USD, significantly exceeding $13.45M USD reported in the comparable nine-month period.

Strong Operating Cash Flow Operating cash flow provided $60.33M USD for nine months, reversing prior year's $7.55M USD cash usage.

Liquidity Position Strengthened Cash and equivalents total $171.96M USD as of September 30, 2025, compared to $155.40M USD at year-end 2024.

リスク要因

EMA Mpox Review Status EMA reassessment procedure ongoing regarding Tecovirimat-SIGA effectiveness for mpox treatment indications, potentially impacting authorization.

Quarterly Revenue Decline Quarterly revenue fell sharply to $2.62M USD in Q3 2025 from $10.01M USD in Q3 2024, resulting in a net loss.

Government Shutdown Uncertainty Prolonged U.S. Government shutdown risks delaying funding decisions, new contract awards, and suspending ongoing contract work.

Tariff Cost Increase Risk Tariff activity involving U.S. and Europe may materially increase IV TPOXX® overall manufacturing costs, impacting margins.

見通し

Smallpox PEP Submission Target Targeting Supplemental NDA submission for oral TPOXX® smallpox post-exposure prophylaxis indication in 2026 based on trial results.

Unexercised BARDA Options Unexercised BARDA options total $5.6M USD, but these supportive activities are currently not expected to be required by BARDA.

Future Purchase Commitments Outstanding purchase orders associated with manufacturing obligations total approximately $12.5M USD as of September 30, 2025.

New Accounting Standard Review Evaluating impact of recently issued FASB ASU 2024-03 regarding expense disaggregation disclosures effective in future periods.

同業比較

売上高 (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$680.39M

+4.4%

粗利益率 (最新四半期)

CTMX

100.0%

+0.0pp

RIGL

91.5%

+7.7pp

KALV

91.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
OLMA	$1.77B	-12.9	-41.5%	1.3%
VTYX	$1.00B	-9.4	-48.1%	4.7%
KALV	$819.36M	-4.2	-282.0%	44.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-68.2%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月9日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし